The global intermediate age-related macular degeneration market is poised for significant growth, driven by the rising aging population and increased ...

EYP-1901 shows promising results in reducing treatment burden for diabetic macular edema, offering sustained improvements in ...

Cataract surgery is the most commonly performed eye surgery in the ophthalmology, with a track record of improving vision and ...

FRONT-1 Phase 3 expected data readout accelerated from H2 2027 to H1 20274FRONT-2 Phase 3 trial initiated ahead of schedule Streamlined late-stage clinical and pre-commercial organization aligns with ...

The treatment of diabetic macular oedema (DMO) likely involves a series of treatment episodes separated by gaps during which ...

Both anti-VEGF and surgical treatments improve VA in AMD-related submacular hemorrhage, with no statistically significant difference between the two treatments. Anti-VEGF injections may be ...

Ixo-vec has demonstrated robust retinal transduction and sustained therapeutic levels, establishing a product profile that was overwhelmingly preferred by LUNA patients over their previous frequent ...

Anti-VEGF injections like aflibercept have been the gold standard of care for years but require frequent administration, leading to treatment gaps and disease progression due to non-adherence.

Study points to approach to improving anti-VEGF therapy for all wet AMD patients, and help subset of patients who lose vision over time despite treatment.

Diabetic macular edema treatment options include anti-vascular endothelial growth factor (anti-VEGF) injections and laser therapy, with patient-specific factors guiding the best approach.

Kidney failure in anti-VEGF treatments occurs at similar rates whether patients receive ranibizumab, bevacizumab, or aflibercept.

Greater vision improvements were seen in people with macular edema secondary to retinal vein occlusion who received more anti-VEGF injections over the course of 5 years.